ArticlePLoS pathogens2026
Defining the impact of Getah virus envelope protein glycosylation site mutations on viral replication, host adaptation, virulence, and immune evasion.
Article in PLoS pathogens, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- N-linked glycosylation of GETV envelope proteins affect viral infection and pathogenicity.Virulence · 2026Article
- Molecular Evolution of the Chikungunya VirusViruses · 2026Article
- The residue 86 of the Getah virus E2 glycoprotein mediates both glycosaminoglycan- and LDLR-dependent infection.PLoS pathogens · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The N-linked glycosylation of alphavirus envelope proteins plays critical roles in glycoprotein folding, host-receptor interactions, immune evasion, and pathogenicity. Getah virus (GETV) has two putative N-linked glycosylation sites (N-200 and N-262) in the E2 and one (N-141) in E1. We generated seven glycosylation-deficient mutants and evaluated their fitness across mammalian cells, mosquitoes, and mouse models. Loss of glycosylation at E2 N-262 or E1 N-141 enhanced in vitro replication and replication efficiency in mosquitoes, while E2 N-200 glycosylation-deficient mutants retained parental replication capacity in vitro but exhibited accelerated mosquito colonization. Despite these gains, glycan loss reduced viral adsorption/entry in selected settings and decreased measurable virion binding to MXRA8 and LDLR in vitro, while single-site E2 glycan mutants exhibited increased heparin sensitivity/affinity, indicating altered utilization of glycosaminoglycan attachment pathways. In vivo, all mutants remained lethal in 3-day-old mice but showed age-dependent attenuation in 10-day-old mice. Notably, E1 N141-deficient mutant induced no clinical symptoms and exhibited reduced viremia and tissue viral loads. Glycan ablation increased susceptibility to neutralization without impairing induction of neutralizing antibodies. Strikingly, E2 mutants rapidly reacquired glycosylation during in vivo replication, indicating strong evolutionary selection for these sites. Together, our data support an evolutionary trade-off in which GETV envelope glycans-particularly the epidemic-lineage-associated E2-N262 glycan-optimize overall fitness by balancing replication/transmission efficiency with humoral immune evasion.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.